Background and Purpose—
18
F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI have been proposed to quantitatively assess plaque inflammation by probing macrophages and neovessels, respectively. We examined their correlation to study the in vivo relationship between macrophage and neovessel activities in atherogenesis.
Methods—
Forty-one patients (34 men; aged 65±12 years) with a total of 68 carotid plaques (thickness ≥2 mm on ultrasound; 20 symptomatic) were assessed by both
18
F-fluorodeoxyglucose positron emission tomography/computed tomography and dynamic contrast-enhanced MRI within 2 weeks, measured as target-to-background ratio and transfer constant (
K
trans
), respectively.
Results—
Overall, the correlation between target-to-background ratio and
K
trans
was weak and marginal (
r
=0.22;
P
=0.068). They were correlated in the symptomatic plaques (
r
=0.59;
P
=0.006) but not in the asymptomatic plaques (
r
=0.07;
P
=0.625;
P
=0.033 for difference in
r
). Neither target-to-background ratio nor
K
trans
was significantly higher in the symptomatic plaques, but both showed an inverse relationship with time since last neurological event (
r
=−0.94 and −0.69 for target-to-background ratio and
K
trans
, respectively).
Conclusions—
The correlation between
18
F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI measurements varied with clinical conditions, pointing to a complex interplay between macrophages and neovessels under different pathophysiological conditions. The moderate correlation shown only in symptomatic plaques indicates the presence of acute plaque inflammation with increased metabolic activity and cytokine production by inflammatory cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.